Risk factors
Ernexa Therapeutics (ERNA) risk factors
Item 1A of every Ernexa Therapeutics Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
34 risks, 2 dropped, 3 reworded since the prior year. The company addressed Nasdaq continued listing requirements after receiving a deficiency notice, noting equity dropped to approximately $2.4 million before a $9.5 million public offering.
Filed Mar 13, 2026 - FY2024 10-K risk factors
36 risks. Capital requirements and ongoing operating losses dominate the risk profile alongside strong reliance on in-licensed technology from Factor Limited.
Filed Mar 12, 2025